NOAH Compendium

Printed from NOAH Compendium (https://www.noahcompendium.co.uk). (c) Copyright NOAH Compendium 2025. All Rights Reserved.
Date: Sunday, July 27, 2025 4:37

Description: Virbac 2013
Release 9.244
Eraquell Oral Paste (NI only)
 
Species: Horses only
Therapeutic indication: Pharmaceuticals: Endoparasiticides: Anthelmintics for horses
Active ingredient: Ivermectin
Product:Eraquell Oral Paste
Product index: Eraquell Oral Paste
Withdrawal notes: Horses: Meat and offal = 30 days; Do not use in mares producing milk for human consumption
Incorporating:
Presentation
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each gram contains:
Active Substance:
Ivermectin ...................................................................... 18.7 mg.
Excipients:
Qualitative composition of excipients and other constituents
Quantitative composition if that information is essential for proper administration of the veterinary medicinal product
Titanium dioxide (E171)
0.02 g
Hydrogenated castor oil
Hydroxypropylcellulose
Propylene glycol
White and thick paste.
Uses
Target species
Horses
Indications for use, specifying the target species
Roundworms in the stomach and intestines.
Large strongyles
Strongylus vulgaris: adults and 4th larval (arterial) stages
Strongylus edentatus: adults and 4th larval (tissue) stages
Strongylus equinus: adults
Small strongyles, adults
Cyathostomum spp.
Cylicocyclus spp.
Cylicodontophorus spp.
Cylicostephanus spp.
Gyalocephalus spp.
Hairworms
Trichostrongylus axei: adults
Pinworms
Oxyuris equi: adults and immatures
Ascarids
Parascaris equorum: adults
Intestinal threadworms
Strongyloides westeri: adults
Large-mouth stomach worms
Habronema muscae: adults
Neck threadworms
Onchocerca spp. (microfilariae)
Lungworms
Dictyocaulus arnfieldi: adult and immature
Stomach bots
Gasterophilus spp.: oral and gastric larval stages
Dosage and administration
ERAQUELL paste is given by mouth at the recommended dose rate of 200 micrograms per kg of bodyweight as a single dose.
Each syringe division delivers sufficient paste to treat 100kg of bodyweight (corresponding to 1.07g product and 20mg ivermectin).
The syringe containing 7.49 g of paste delivers sufficient paste to treat 700 kg of bodyweight at the recommended dose range.
The horse’s weight should be accurately determined to ensure use of the correct dose of product.
Directions for use:
To ensure a correct dosage, body weight should be determined as accurately as possible. The animal's mouth should be free of food. The syringe must be positioned between the front and back teeth and the paste must be placed on the base of the horse’s tongue. Immediately elevate the head of the horse for a few seconds to ensure deglutition.
Re-treatment should be done according to the epidemiological situation, but not at less than 30 days interval. situation and at not less than 30 day intervals.
Contra-indications, warnings, etc
Contraindications
Do not use in dogs or cats as severe adverse reactions may occur.
Do not use in cases of known hypersensitivity to the active substance.
See also “Withdrawal periods”.
Special warnings for each target species
Strategies that should be avoided because they might lead to an increased risk of development of resistance to anthelmintic drugs include:
Too frequent and repeated use of anthelmintics from the same class over an extended period of time.
Underdosing, which may be due to underestimation of body weight, misadministration of the product, or lack of calibration of the dosing device (if any).
Suspected clinical cases of resistance to anthelmintics should be further investigated using appropriate tests. Where the results of the test(s) strongly suggest resistance to a particular anthelmintic, an anthelmintic belonging to another pharmacological class and having a different mode of action should be used.
Resistance to ivermectin has been reported in Parascaris equorum in horses. Therefore the use of this product should be based on local (regional, farm) epidemiological information about susceptibility of nematodes and recommendations on how to limit further selection for resistance to anthelmintics.
Special precautions for use
Special precautions for use in animals
Parasite resistance to any particular class of anthelmintic may develop following frequent, repeated use of an anthelmintic of that class.
Since ivermectin is highly bound to plasma proteins, special care should be taken in cases of sick animals or in nutritional conditions associated with low plasma protein levels.
As with all anthelmintics, a veterinary surgeon should establish appropriate dosing programs and stock management to achieve adequate parasite control and reduce the likelihood of anthelmintic resistance.
Special precautions to be taken by the person administering the veterinary medicinal product to animals:
Do not eat, drink or smoke while handling the product. Avoid contact with skin and eyes. If accidental skin contact occurs, wash the affected area immediately with soap and water. If accidental eye exposure occurs, flush the eyes immediately with water and, if necessary, get medical attention.
Wash hands after use.
Special precautions for the protection of the environment:
As ivermectin is extremely dangerous to fish and aquatic life treated animals should not have direct access to surface water and ditches during treatment.
Other precautions:
Avermectins may not be well tolerated in all non-target species (cases of intolerance with fatal outcome are reported in dogs, especially Collies, Old English Sheepdogs and related breeds or crosses, and also in turtles/tortoises).
Adverse reactions
Horses:
Undetermined Frequency (cannot be estimated from the available data)
Swelling* Itching*
*For some horses carrying heavy infection of Onchocerca microfilariae and assumed to be the result of death of large numbers of microfilariae. These signs resolve within a few days but symptomatic treatment may be advisable.
Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or its local representative or the national competent authority via the national reporting system. See the package leaflet for respective contact details.
Use during pregnancy and lactation
Can be used in pregnant mares. See “Withdrawal periods”.
Interaction with other medicinal products and other forms of interaction
The effects of GABA agonists are increased by ivermectin.
Overdose
Mild transitory signs (slowed pupillary light response and depression) have been seen at a higher dose of 1.8 mg/kg (9 times the recommended dose level). Other signs seen at higher doses include mydriasis, ataxia, tremors, stupor, coma and death. The less severe signs have been transitory. Although no antidote has been identified, symptomatic therapy may be beneficial.
Withdrawal period
Meat and offal : 30 days.
Do not use in mares producing milk for human consumption.
Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products
Medicines should not be disposed of via wastewater or household waste.
The veterinary medicinal product should not enter water courses as ivermectin is extremely dangerous for fish and other aquatic organisms.
Use take-back schemes for the disposal of any unused veterinary medicinal product or waste material derived thereof of in accordance with local requirements and with any national collection systems applicable to the veterinary medicinal product concerned.
Do not contaminate surface water or ditches with the veterinary medicinal product or used containers.
Pharmaceutical precautions
Incompatibilities
Not applicable.
Shelf life
Shelf life of the veterinary medicinal product as packaged for sale: 2 years.
Shelf-life after first opening of the container: 6 months.
Special precautions for storage
Do not store above 30°C.
Store in the original packaging.
Legal category
Legal category: POM-VPS
Packaging quantities
The product is presented in 6.42 g or 7.49 g plastic syringes made from polyethylene and graduated in 100 kg body weight graduations.
Product presentations
6.42 g syringe: Box of 1, 2, 12, 40 or 48 syringes. Transparent PVC blister sealed onto a carton sheet containing one syringe
7.49 g syringe: Box of 1, 2, 12, 40 or 48 syringes. Transparent PVC blister sealed onto a carton sheet containing one syringe
Not all pack sizes may be marketed.
Further information
PHARMACOLOGICAL INFORMATION
ATCvet code : QP 54 AA 01
Pharmacodynamics
Ivermectin is a macrocyclic lactone derivative and acts by inhibiting nerve impulses. It binds selectively and with high affinity to glutamate-gated chloride ion channels which occur in invertebrate nerve and muscle cells. This leads to an increase in the permeability of the cell membrane to chloride ions with hyperpolarization of the nerve or muscle cell, resulting in paralysis and death of the relevant parasites. Compounds of this class may also interact with other ligand-gated chloride channels, such as those gated by the neurotransmitter gamma-aminobutyric acid (GABA). The margin of safety for compounds of this class is attributable to the fact that mammals do not have glutamate-gated chloride channels. The macrocyclic lactones have a low affinity for other mammalian ligand-gated chloride channels and they do not readily cross the blood-brain barrier.
Pharmacokinetics
After oral administration of the recommended doses to horses, the following parameters were observed: Cmax of 48.79 ng/ml, Tmax of 5.5 hours, elimination half-life of 61 hours. Ivermectin is eliminated primarily via the faeces.
Marketing Authorisation Number
Vm 05653/3013
Significant changes
GTIN
GTIN description:Eraquell 7.49g Syringe
GTIN:3597133010893
GTIN description:Eraquell Yard Pack 7.49g Syringe x 28
GTIN:3597133043853